Pfizer
Pfizer returns on capital
Annual and trailing 12-month returns on invested capital, equity and assets.
ROIC
% · Annual / TTM
NOPAT is undefined under this method: pretax profit must be positive and the effective tax rate must be between 0 and 100%.
ROCE
% · Annual / TTM
Operating income is unavailable in the extracted statements for this period.
ROIIC
% · Annual / TTM
Invested capital did not increase versus the prior year. ROIIC requires a positive increase.
ROE
% · Annual / TTM
ROA
% · Annual / TTM
ROIC − WACC
Percentage points · Scenario
NOPAT is undefined under this method: pretax profit must be positive and the effective tax rate must be between 0 and 100%.
Quarterly data
| Fiscal period | Ended | ROIC% | ROCE% | ROIIC% | ROE% | ROA% | ROIC − WACCPercentage points |
|---|---|---|---|---|---|---|---|
| FY 2026 Q2 | Jun 28, 2026 | — | — | — | 4.98% | 2.13% | — |
| FY 2026 Q1 | Mar 29, 2026 | — | — | — | 8.3% | 3.6% | — |
| FY 2025 Q4 | Dec 31, 2025 | — | — | — | 8.9% | 3.69% | — |
| FY 2025 Q3 | Sep 28, 2025 | — | — | — | 10.62% | 4.59% | — |
| FY 2025 Q2 | Jun 29, 2025 | — | — | — | 12.19% | 5.09% | — |
| FY 2025 Q1 | Mar 30, 2025 | — | — | — | 8.63% | 3.67% | — |
| FY 2024 Q4 | Dec 31, 2024 | — | — | — | 9.06% | 3.65% | — |
| FY 2024 Q3 | Sep 29, 2024 | — | — | — | 4.49% | 1.96% | — |
| FY 2024 Q2 | Jun 30, 2024 | — | — | — | -2.78% | -1.19% | — |
| FY 2024 Q1 | Mar 31, 2024 | — | — | — | -0.32% | -0.15% | — |
| FY 2023 Q4 | Dec 31, 2023 | — | — | — | 2.29% | 1% | — |
| FY 2023 Q3 | Oct 1, 2023 | — | — | — | 11.06% | 5.11% | — |
| FY 2023 Q2 | Jul 2, 2023 | — | — | — | 23.06% | 10.34% | — |
| FY 2023 Q1 | Apr 2, 2023 | — | — | — | 31.68% | 15.31% | — |
| FY 2022 Q4 | Dec 31, 2022 | — | — | — | 36.3% | 16.57% | — |
| FY 2022 Q3 | Oct 2, 2022 | — | — | — | 35.37% | 15.9% | — |
| FY 2022 Q2 | Jul 3, 2022 | — | — | — | 37.28% | 16.05% | — |
| FY 2022 Q1 | Apr 3, 2022 | — | — | — | 33.06% | 14.57% | — |
| FY 2021 Q4 | Dec 31, 2021 | — | — | — | 31.3% | 13.09% | — |
| FY 2021 Q3 | Oct 3, 2021 | — | — | — | 27.22% | 10.71% | — |
| FY 2021 Q2 | Jul 4, 2021 | — | — | — | 19.69% | 7.61% | — |
| FY 2021 Q1 | Apr 4, 2021 | — | — | — | 16.6% | 6.82% | — |
| FY 2020 Q4 | Dec 31, 2020 | — | — | — | 15.22% | 5.98% | — |
| FY 2020 Q3 | Sep 27, 2020 | — | — | — | 13.32% | 4.97% | — |
| FY 2020 Q2 | Jun 28, 2020 | — | — | — | 22.87% | 8.48% | — |
| FY 2020 Q1 | Mar 29, 2020 | — | — | — | 25.5% | 9.82% | — |
| FY 2019 Q4 | Dec 31, 2019 | — | — | — | 25.72% | 9.96% | — |
| FY 2019 Q3 | Sep 29, 2019 | — | — | — | 23.77% | 9.59% | — |
| FY 2019 Q2 | Jun 30, 2019 | — | — | — | 19.56% | 7.88% | — |
| FY 2019 Q1 | Mar 31, 2019 | — | — | — | — | — | — |
| FY 2018 Q4 | Dec 31, 2018 | — | — | — | — | — | — |
| FY 2018 Q3 | Sep 30, 2018 | — | — | — | — | — | — |
| FY 2018 Q2 | Jul 1, 2018 | — | — | — | — | — | — |
| FY 2014 Q2 | Jun 29, 2014 | — | — | — | 13.41% | 5.91% | — |
| FY 2014 Q1 | Mar 30, 2014 | — | — | — | 26.98% | 12.02% | — |
| FY 2013 Q4 | Dec 31, 2013 | — | — | — | 27.93% | 12.3% | — |
| FY 2013 Q3 | Sep 29, 2013 | — | — | — | 32.25% | 14.38% | — |
| FY 2013 Q2 | Jun 30, 2013 | — | — | — | 33.35% | 14.56% | — |
| FY 2013 Q1 | Mar 31, 2013 | — | — | — | 18.75% | 8.32% | — |
| FY 2012 Q4 | Dec 31, 2012 | — | — | — | 17.83% | 7.8% | — |
| FY 2012 Q3 | Sep 30, 2012 | — | — | — | 11.29% | 5.12% | — |
| FY 2012 Q2 | Jul 1, 2012 | — | — | — | 12.17% | 5.4% | — |
| FY 2012 Q1 | Apr 1, 2012 | — | — | — | 11.05% | 5.03% | — |
| FY 2011 Q4 | Dec 31, 2011 | — | — | — | 11.77% | 5.23% | — |
| FY 2011 Q3 | Oct 2, 2011 | — | — | — | 12.9% | 5.91% | — |
| FY 2011 Q2 | Jul 3, 2011 | — | — | — | 9.82% | 4.44% | — |
| FY 2011 Q1 | Apr 3, 2011 | — | — | — | 9.4% | 4.33% | — |
| FY 2010 Q4 | Dec 31, 2010 | — | — | — | 9.28% | 4.05% | — |
| FY 2010 Q3 | Oct 3, 2010 | — | — | — | 7.97% | 3.69% | — |
| FY 2010 Q2 | Jul 4, 2010 | — | — | — | 10.9% | 4.93% | — |
| FY 2010 Q1 | Apr 4, 2010 | — | — | — | — | — | — |
| FY 2009 Q4 | Dec 31, 2009 | — | — | — | — | — | — |
| FY 2009 Q3 | Sep 27, 2009 | — | — | — | — | — | — |
| FY 2009 Q2 | Jun 28, 2009 | — | — | — | — | — | — |
Sources and calculations
Financial inputs from company filings. Last checked Oct 18, 2026. A dash means missing inputs or an undefined calculation.
Period changes use the preceding fiscal quarter or year. Percentage changes divide by the absolute prior value; a zero or missing baseline has no percentage change. Percentage metrics show changes in percentage points.
Quarterly returns use trailing 12-month earnings and period-end balances averaged with the same fiscal quarter one year earlier. NOPAT uses the reported effective tax rate only when pretax profit is positive and the rate is between 0 and 100%. WACC starts at 7.9%, rounded from the Pharmaceuticals benchmark in NYU Stern · January 2026. It is an editable US sector proxy applied across history, not a company estimate; foreign reporting currencies also need a currency-specific assessment.
Market prices: Yahoo Finance · PFE, USD. Latest completed close Sep 25, 2026. Price data retrieved Sep 28, 2026.
- ROIC
- NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
- ROCE
- Operating income / average (assets − current liabilities) × 100, using period end and one year earlier.
- ROIIC
- Year-over-year change in annual/TTM NOPAT / positive year-over-year change in invested capital × 100. Capital reductions and missing inputs yield unavailable values.
- ROE
- Earnings attributable to owners / average equity attributable to owners × 100, using period end and one year earlier.
- ROA
- Net income / average total assets × 100, using period end and one year earlier.
- ROIC − WACC
- ROIC less your WACC assumption, in percentage points. The same scenario rate is applied across history; it is not a reported or historical company WACC.